Immune-biomarkers for evaluation of clinical activity of VEGFR-targeted vaccines against malignant glioma patients

2014 Fiscal Year Final Research Report

• Project/Area Number: 24592172
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Cerebral neurosurgery
• Research Institution: Keio University
• Principal Investigator: UEDA RYO 慶應義塾大学, 医学部, 共同研究員 (30317143)
• Co-Investigator(Renkei-kenkyūsha): TODA Masahiro 慶應義塾大学, 医学部, 准教授 (20217508)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 悪性神経膠腫 / がんペプチドワクチン / 抗腫瘍免疫 / 腫瘍血管新生

Outline of Final Research Achievements

Immune-biomarkers and -assays are important for development of cancer immunotherapy to monitor immune induction following immunotherapy, and to evaluate anti-tumor effects early after immunotherapy. We characterized status of immune cells, cytokines, chemokines and other immunosuppressive molecules in recurrent malignant glioma patients who received vaccinations of VEGF receptor peptides. Peripheral blood samples from patients who demonstrated positive radiologic response or stable disease revealed superior VEGFR-specific CTL reactivity and lower level of serum VEGF compared to samples from other patients with progressing malignant glioma. These data indicate that these parameters may be potential immune-biomarkers for evaluation of clinical activity of VEGFR-targeted vaccines.

Free Research Field

脳神経外科学